

### UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/978,152	10/16/2001	Sau-Spence Leung	5855-03-ВНЈ	4192		
7:	590 11/06/2002					
Warnr-Lambert Company			EXAMI	EXAMINER		
201 Tabor Rd. Morris Plains, l	NJ 07950		WEDDINGTO	N, KEVIN E		
			ART UNIT	PAPER NUMBER		
			1614	2		
			DATE MAILED: 11/06/2002	$\mathcal{D}$		

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 09/978,152

Applicant(s)

Leung et al.

Examiner

Kevin E. Weddington

Art Unit 1614



The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.							
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.							
If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  Feilure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) 💢	Responsive to communication(s) filed on <u>Aug 26, 2</u>	002			· · ·		
2a) 💢	This action is <b>FINAL</b> . 2b) $\square$ This action	ion is non	final.				
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposit	tion of Claims						
4) 💢	Claim(s) <u>26-41</u>				is/are pending in the application.		
4	a) Of the above, claim(s)				is/are withdrawn from consideration.		
5) 🗆	Claim(s)				is/are allowed.		
6) 💢	Claim(s) 26-41				is/are rejected.		
7) 🗆	Claim(s)				is/are objected to.		
8) 🗆	Claims		_ are su	ubject	to restriction and/or election requirement.		
Applica	tion Papers						
9) 🗆	The specification is objected to by the Examiner.						
10)	The drawing(s) filed on is/are	a) 🗆 acc	epted o	or b)[	$\square$ objected to by the Examiner.		
	Applicant may not request that any objection to the di	rawing(s) t	e held i	in abey	vance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on		is: a)	□ a	pproved b) $\square$ disapproved by the Examiner.		
	If approved, corrected drawings are required in reply t	o this Offi	ce actio	n.			
12)	The oath or declaration is objected to by the Examin	ner.					
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) [	] All b)□ Some* c)□ None of:						
	1. $\square$ Certified copies of the priority documents have	e been red	ceived.				
:	2. $\square$ Certified copies of the priority documents have	e been red	ceived i	n App	lication No		
	<ol> <li>Copies of the certified copies of the priority do application from the International Burea</li> </ol>	au (PCT R	ule 17	2(a)).	-		
	ee the attached detailed Office action for a list of the			•			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
a) U The translation of the foreign language provisional application has been received.							
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachm	ent(s) tice of References Cited (PTO-892)	4) 🗆	iou C	on/ /DTA	9-413) Paper No(s).		
_	tice of Draftsperson's Patent Drawing Review (PTO-948)	_		-	Application (PTO-152)		
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)							
	· · · · · · · · · · · · · · · · · · ·						

Application/Control Number: 09/978,152

Page 2

Art Unit: 1614

Claims 26-41 are presented for examination.

Applicants' amendment filed August 26, 2002 has been received and entered.

## **Priority**

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in PCT/US00/02079 on 1/27/200. It is noted, however, that applicant has not filed a certified copy of the said application as required by 35 U.S.C. 119(b).

## **Double Patenting**

Claims 26-41 are again rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,329,343. Although the conflicting claims are not identical, they are not patentably distinct from each other because the present application is claiming a bioadhesive composition comprising a film forming agent, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acid adapted to resuscitate injured mammalian cells; and the patented application is again claiming a bioadhesive composition comprising a film forming phase, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acid while the film forming phase comprising pullulan. N

Application/Control Number: 09/978,152

Page 3

Art Unit: 1614

Note the present application's film forming agent is selected from a Markush group containing pullulan. The present application further comprising additional additives such as an anesthetic agent and an anti-microbial agent. Note the patented application specification located in column 4, lines 36-64 teaches the addition of "pharmaceutically active agents" which includes anesthetic agents and anti-microbial agents along with others as set forth in present application claims 40 and 41. Clearly, the one skilled in the art would have been motivated to add the additional "pharmaceutically active agents" to the now patented bioadhesive composition to formulate the instant bioadhesive composition of the present application in the absence of evidence to the contrary.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

Application/Control Number: 09/978,152 Page 4

Art Unit: 1614

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 26-41 are not allowed.

### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner K. Weddington whose telephone number is (703) 308-1235.

Kevin E. Weddington
Primary Examiner
Art Unit 1614

K. Weddington

November 5, 2002